Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05032833 | Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects | PHASE1 | COMPLETED | 36 | — | — | Sep 22, 2021 | Jul 7, 2022 | Oct 12, 2022 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 5-MeO-DMT arm | EXPERIMENTAL | - |
| Placebo arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 5-MeO-DMT | DRUG | A single dose of 5-MeO-DMT will be administered intranasally |
| Placebo | OTHER | A single dose of placebo will be administered intranasally |
Inclusion Criteria: \* Medically healthy based on medical records and study specific assessments Exclusion Criteria: \* Presence or history of severe adverse reaction to any drug or drug excipient